Smith & Nephew
), the global medical technology business, declared the
introduction of its latest offering, Regranex360. It is a
comprehensive program devised to provide support to U.S. patients
using REGRANEX Gel.
BIO-RAD LABS -A (BIO): Free Stock Analysis
BOSTON SCIENTIF (BSX): Free Stock Analysis
RESMED INC (RMD): Free Stock Analysis Report
SMITH & NEPHEW (SNN): Free Stock Analysis
To read this article on Zacks.com click here.
REGRANEX Gel is the first and only FDA-approved available
platelet-derived growth factor (PDGF) therapy that can be used
for the treatment of lower extremity diabetic neuropathic ulcers.
Regranex360 is a full service online portal that seeks to
simplify the previous authorization and product acquisition
process. The patient-friendly portal offers patients the scope to
receive advice from a care coordinator via phone throughout the
entire course of the therapy. In addition, respective patient
care coordinators will contact their patients to schedule
delivery, provide valuable education and resolve doubts related
Moreover, patients are also given a chance to find answers to
their queries using the Regranex360 hotline during their course
of the therapy. Such specialized services will not only make the
online portal customer-friendly and popular, but will also help
it to adhere and comply with the REGRANEX Gel.
Regranex360 is simple to use and access. Following the submission
of the enrollment forms by the clinicians either through
Regranex360.com or via fax, the portal starts the process of
obtaining the authorization approval. The prescription is then
sent to an appropriate pharmacy.
Besides the Regranex360 program, Smith & Nephew
Biotherapeutics has also introduced a new REGRANEX Gel Web site
which highlights the features of the product including clinical
research, complemented by a dosing calculator and additional tips
The new offering from Smith & Nephew Biotherapeutics reflects
the commitment of the company to offer evidence-based biologic
therapeutics. It is believed to be one of the best-in-class
providers of patient support programs, designed especially for
the wound care market. The company's online portal is expected to
streamline and improve the REGRANEX Gel patient experience, going
SNN currently carries a Zacks Rank #3 (Hold). Other stocks that
are worth a look include
Bio-Rad Laboratories, Inc.
) carrying a Zacks Rank #1 (Strong Buy), and
Boston Scientific Corp.
), each carrying a Zacks Rank #2 (Buy).